Table 2.

MMSE scores

	Baseline	3 h Post	ΔMMSE at 3 h
Placebo (n = 3)	22.00±1.53	21.00±2.00	–1.00±1.53
Bryostatin (n = 6)	21.33±1.50	23.16±1.89	+1.83±0.70

Bryostatin Efficacy on Cognitive Function in blinded Phase IIa trial. A single i.v. infusion was followed 3 h, 4 d, and 15 d after infusion by a cognitive evaluation with the Mini-Mental State Examination-2 (MMSE-2). MMSE scores in bryostatin-treated subjects were increased at 3 h (p = 0.041, paired t-test). MMSE scores of the treated groups at other times or of the placebos at 3 h were not significantly different from the corresponding baseline values.